Analysis of Antidepressant-like Effects and Action Mechanisms of GSB-106, a Small Molecule, Affecting the TrkB Signaling
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Induction of BDNF-TrkB signaling is associated with the action mechanisms of conventional and fast-acting antidepressants. GSB-106, developed as a small dimeric dipeptide mimetic of BDNF, was previously shown to produce antidepressant-like effects in the mouse Porsolt test, tail suspension test, Nomura water wheel test, in the chronic social defeat stress model and in the inflammation-induced model of depression. In the present study, we evaluated the effect of chronic per os administration of GSB-106 to Balb/c mice under unpredictable chronic mild stress (UCMS). It was observed for the first time that long term GSB-106 treatment (1 mg/kg, 26 days) during ongoing UCMS procedure ameliorated the depressive-like behaviors in mice as indicated by the Porsolt test. In addition, chronic per os administration of GSB-106 resulted in an increase in BDNF levels, which were found to be decreased in the prefrontal cortex and hippocampus of mice after UCMS. Furthermore, prolonged GSB-106 treatment was accompanied by an increase in the content of pTrkB706/707 in the prefrontal cortex and by a pronounced increase in the level of pTrkB816 in both studied brain structures of mice subjected to UCMS procedure. In summary, the present data show that chronic GSB-106 treatment produces an antidepressant-like effect in the unpredictable chronic mild stress model, which is likely to be associated with the regulation of the BDNF-TrkB signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two BDNF mimickers currently under investigation are dipeptide N-monosuccinyl-L-seryl-L-lysine and 7,8-Dihydroxyflavone (187).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [187]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu121 · Cited by 103 · cited 1×
“It is well known that long-term exposure to stress, as well as other conditions that contribute to the depressive-like behavior in animals, is accompanied by a BDNF expression decrease in the prefrontal cortex and in the hippocampus, while an increase in the level of neurotrophin has been observed in the nucleus accum…”
BackgroundRetractedRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“However, the long onset time for antidepressants effects (several weeks to months), a significant number of patients that do not respond to typical antidepressants and a broad range of side effects significantly limit the efficacy of treatment [12].”
BackgroundThe Neuroendocrinology of Stress: A Never Ending Story
Lightman, S. L. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01711.x · Cited by 3,566
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375 · cited 5×
“It has been widely shown that chronic stress-induced behavioral changes are associated with neuronal atrophy and reduced levels of BDNF and phosphorylated/activated TrkB in the prefrontal cortex and the hippocampus in rodents, while almost all antidepressants can restore BDNF level and activate TrkB receptors in roden…”
BackgroundResultInfluentialNestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 2×
“Numerous basic research findings confirm that typical antidepressants increase the BDNF mRNA and protein expression as well as the TrkB activation in the hippocampus and the cortex [3,7,15], thus promoting the structural plastic changes associated with the antidepressant action mechanisms [8,16,17].”
BackgroundNibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 2×
“Numerous basic research findings confirm that typical antidepressants increase the BDNF mRNA and protein expression as well as the TrkB activation in the hippocampus and the cortex [3,7,15], thus promoting the structural plastic changes associated with the antidepressant action mechanisms [8,16,17].”
BackgroundWillner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 1×
“Numerous basic research findings confirm that typical antidepressants increase the BDNF mRNA and protein expression as well as the TrkB activation in the hippocampus and the cortex [3,7,15], thus promoting the structural plastic changes associated with the antidepressant action mechanisms [8,16,17].”
BackgroundSustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750 · cited 1×
“Experimental studies have reported that the delayed onset of antidepressants action is associated with a slowly developed increase and rearrangements of synaptic strength in the depressionrelated circuits, requiring changes in the gene expression and protein translation that are dependent, to some extent, on the engag…”
BackgroundBrain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654 · cited 1×
“Although the intracerebral administration of BDNF produced an antidepressant-like effect in animal models of depression [30,31], clinical use of neurotrophin is limited, mainly due to its suboptimal pharmacokinetic properties and side effects.”
BackgroundSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 1×
“Numerous basic research findings confirm that typical antidepressants increase the BDNF mRNA and protein expression as well as the TrkB activation in the hippocampus and the cortex [3,7,15], thus promoting the structural plastic changes associated with the antidepressant action mechanisms [8,16,17].”
BackgroundBrain-Derived Neurotrophic Factor and Neuropsychiatric Disorders
Autry, A. E., & Monteggia, L. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005108 · Cited by 1,390 · cited 1×
“Overall, a number of previous observations as well as some more recent evidence emphasize the significance of TrkB as a valuable target for antidepressants [23,24] and reaffirm the critical role of BDNF/TrkB signaling in the pathophysiology of depression and in antidepressants action [7,25,26].”
ResultLower Hippocampal Volume in Patients Suffering From Depression: A Meta-Analysis
Campbell, S., Marriott, M., Nahmias, C., & MacQueen, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.598 · Cited by 1,156
The chronic mild stress (CMS) model of depression: History, evaluation and usage
Willner, P. (2017) · Neurobiology of Stress · doi:10.1016/j.ynstr.2016.08.002 · Cited by 959 · cited 1×
“Based on its close resemblance to certain human depressive symptoms, unpredictable chronic mild stress (UCMS) is considered as one of the most translationally-relevant and valuable models for studying the pathophysiology of depression and the efficacy of antidepressants in animals [47].”
BackgroundCastrén, E., & Rantamäki, T. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20758 · Cited by 864 · cited 1×
“Numerous basic research findings confirm that typical antidepressants increase the BDNF mRNA and protein expression as well as the TrkB activation in the hippocampus and the cortex [3,7,15], thus promoting the structural plastic changes associated with the antidepressant action mechanisms [8,16,17].”
BackgroundAntidepressant-like effect of brain-derived neurotrophic factor (BDNF)
Siuciak, J. A., Lewis, D. R., Wiegand, S. J., & Lindsay, R. M. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00169-4 · Cited by 841 · cited 1×
“Although the intracerebral administration of BDNF produced an antidepressant-like effect in animal models of depression [30,31], clinical use of neurotrophin is limited, mainly due to its suboptimal pharmacokinetic properties and side effects.”
BackgroundSaarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800 · cited 2×
“Our results on the tyrosine-specific phosphorylation of TrkB (Tyr706/707 and Tyr816 sites, but not at Tyr515) in the brain areas implicated in depression, caused by prolonged GSB-106 treatment in UCMS-exposed mice, are in line with the data observed on typical antidepressants, which provide TrkB-Tyr816/PLC-γ1 specific…”
BackgroundResultDuman, R. S., & Voleti, B. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.004 · Cited by 714 · cited 1×
“It is widely believed that chronic antidepressant treatment causes an increase in the synthesis or release of BDNF, activation of TrkB receptors and related signal transduction pathways, triggers up-regulation of genes associated with BDNF-induced plasticity [7,24,70,71].”
BackgroundA selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone
Jang, S.-W., Liu, X., Yepes, M., Shepherd, K. R., Miller, G. W., Liu, Y., Wilson, W. D., Xiao, G., Blanchi, B., Sun, Y. E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913572107 · Cited by 686 · cited 3×
“ability to directly interact with the extracellular domain of TrkB and promote receptor dimerization was reported only for 7,8-dihydroxyflavone amongst the low-molecular weight putative ligands of TrkB with antidepressant properties [32].”
BackgroundAntidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663
“Behavioural despair” in rats and mice: Strain differences and the effects of imipramine
Porsolt, R. D., Bertin, A., & Jalfre, M. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90414-4 · Cited by 636 · cited 1×
“The antidepressant activity was studied in the Porsolt test in mice [89].”
MethodBessa, J. M., Ferreira, D., Melo, I., Marques, F., Cerqueira, J. J., Palha, J. A., Almeida, O. F. X., & Sousa, N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.119 · Cited by 598 · cited 1×
“Prolonged activation of the HPA axis under chronic stress causes prolonged release of glucocorticoids which are toxic both for the hippocampus and the frontal cortex which leads to a decrease in the BDNF content [61,62], depletion of synaptic connections [63] and their morphological decrease develop [63,64].”
BackgroundPathogenesis of depression: Insights from human and rodent studies
Ménard, C., Hodes, G. E., & Russo, S. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.053 · Cited by 593
Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action
Castrén, E., & Monteggia, L. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.008 · Cited by 540 · cited 1×
“Overall, a number of previous observations as well as some more recent evidence emphasize the significance of TrkB as a valuable target for antidepressants [23,24] and reaffirm the critical role of BDNF/TrkB signaling in the pathophysiology of depression and in antidepressants action [7,25,26].”
ResultMechanism of TrkB-Mediated Hippocampal Long-Term Potentiation
Minichiello, L., Calella, A. M., Medina, D. L., Bonhoeffer, T., Klein, R., & Korte, M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00942-x · Cited by 506
Dendritic Spines in Depression: What We Learned from Animal Models
Qiao, H., Li, M.-X., Xu, C., Chen, H.-B., An, S.-C., & Ma, X.-M. (2016) · Neural Plasticity · doi:10.1155/2016/8056370 · Cited by 446
Neurobiology of chronic mild stress: parallels to major depression
Hill, M. N., Hellemans, K. G. C., Verma, P., Gorzalka, B. B., & Weinberg, J. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.07.001 · Cited by 420 · cited 2×
“001 respectively) of mice exposed to UCMS, compared to the control non-stressed animals, which is consistent with the previous data [54,55].”
ResultExercise, Antidepressant Medications, and Enhanced Brain Derived Neurotrophic Factor Expression
Russo-Neustadt, A. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00059-7 · Cited by 411
Cazorla, M., Prémont, J., Mann, A., Girard, N., Kellendonk, C., & Rognan, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43992 · Cited by 392 · cited 6×
“Currently, several compounds with antidepressant properties were identified as putative ligands of the TrkB receptor, such as 7,8-dihydroxyflavone (TrkB agonist), ANA-12 (TrkB antagonist) and tetraterpenoid deoxygedunin.”
BackgroundInfluentialRusso-Neustadt, A., Ha, T., Ramirez, R., & Kesslak, J. P. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00364-8 · Cited by 346
Rantamäki, T., Hendolin, P., Kankaanpää, A., Mijatovic, J., Piepponen, P., Domenici, E., Chao, M. V., Männistö, P. T., & Castrén, E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301345 · Cited by 305 · cited 3×
“However, phosphorylation at Tyr816 residue in the mice hippocampus was detected 1 h after acute administration of fluoxetine, riboxetine, citalopram, imipramine; a similar effect on the phosphorylation of Tyr816 was also established upon long-term administration (21 days) of fluoxetine [19].”
BackgroundResultAltar, C. A., Whitehead, R. E., Chen, R., Wörtwein, G., & Madsen, T. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00073-8 · Cited by 300
Longo, F. M., & Massa, S. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4024 · Cited by 298 · cited 2×
“One of the ways to overcome these factors is to augment BDNF/TrkB pathway with small molecules that could function as TrkB ligands or enhance neurotrophin signaling [27].”
BackgroundGRONLI, J., MURISON, R., FISKE, E., BJORVATN, B., SORENSEN, E., PORTAS, C., & URSIN, R. (2005) · Physiology & Behavior · doi:10.1016/j.physbeh.2005.02.007 · Cited by 291 · cited 1×
“The UCMS model was used to induce chronic stress conditions [88].”
MethodZhang, J.-C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., Li, S.-X., Shirayama, Y., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu077 · Cited by 289 · cited 1×
“The antidepressant properties of 7,8-dihydroxyflavone and ANA-12 as well as their ability to increase BDNF and pTrkB-Tyr706/707 levels have also been demonstrated in a social defeat stress model and LPS-stimulated depressive-like behavior [81,82].”
BackgroundLucassen, P. J., Müller, M. B., Holsboer, F., Bauer, J., Holtrop, A., Wouda, J., Hoogendijk, W. J. G., De Kloet, E. R., & Swaab, D. F. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63988-0 · Cited by 286 · cited 1×
“Lower volume of hippocampal and prefrontal cortex found in the subjects with depression are believed to be related to the neuronal atrophy through an increase in the apoptosis-associated DNA fragmentation and necrotic neuron death, as well as with alterations of synaptic reorganization proteins and, predominantly, wit…”
BackgroundAnimal Models of Depression: Utility for Transgenic Research
Porsolt, R. D. (2000) · Reviews in the Neurosciences · doi:10.1515/revneuro.2000.11.1.53 · Cited by 285
Dias, B. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00198-9 · Cited by 274
Grønli, J., Bramham, C., Murison, R., Kanhema, T., Fiske, E., Bjorvatn, B., Ursin, R., & Portas, C. M. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.11.021 · Cited by 260 · cited 1×
“Prolonged activation of the HPA axis under chronic stress causes prolonged release of glucocorticoids which are toxic both for the hippocampus and the frontal cortex which leads to a decrease in the BDNF content [61,62], depletion of synaptic connections [63] and their morphological decrease develop [63,64].”
BackgroundDi Chiara, G., Loddo, P., & Tanda, G. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00236-x · Cited by 258 · cited 1×
“The chronic stress activation causes a decrease in the activity of the mesolimbic dopamine system, which may lead to the development of anhedonia as a result of stress which could be a target of antidepressant effect [69].”
BackgroundNeurotrophic effects of antidepressant drugs
CASTREN, E. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.10.004 · Cited by 244 · cited 1×
“It is widely believed that chronic antidepressant treatment causes an increase in the synthesis or release of BDNF, activation of TrkB receptors and related signal transduction pathways, triggers up-regulation of genes associated with BDNF-induced plasticity [7,24,70,71].”
BackgroundLiu, X., Chan, C.-B., Jang, S.-W., Pradoldej, S., Huang, J., He, K., Phun, L. H., France, S., Xiao, G., Jia, Y., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101206p · Cited by 208 · cited 2×
“The best characterized and well-studied examples are the 7,8-dihydroxyflavone [32,33] and its synthetic derivative [34], the low-molecular weight TrkB antagonist with anxiolytic”
BackgroundFilho, C. B., Jesse, C. R., Donato, F., Giacomeli, R., Del Fabbro, L., da Silva Antunes, M., de Gomes, M. G., Goes, A. T. R., Boeira, S. P., Prigol, M., et al. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.12.048 · Cited by 200 · cited 1×
“Prolonged activation of the HPA axis under chronic stress causes prolonged release of glucocorticoids which are toxic both for the hippocampus and the frontal cortex which leads to a decrease in the BDNF content [61,62], depletion of synaptic connections [63] and their morphological decrease develop [63,64].”
BackgroundZhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., & Hashimoto, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4062-3 · Cited by 183 · cited 1×
“The antidepressant properties of 7,8-dihydroxyflavone and ANA-12 as well as their ability to increase BDNF and pTrkB-Tyr706/707 levels have also been demonstrated in a social defeat stress model and LPS-stimulated depressive-like behavior [81,82].”
BackgroundMouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey
Yalçın, İ., Belzung, C., & Surget, A. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.04.021 · Cited by 183 · cited 1×
“Most studies usually raise the question of drug efficacy in the settings of the developed behavioral abnormalities, and the course of potential antidepressants is initiated after several weeks of ongoing stress stimuli [53].”
BackgroundKoponen, E., Võikar, V., Riekki, R., Saarelainen, T., Rauramaa, T., Rauvala, H., Taira, T., & Castrén, E. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.01.006 · Cited by 170
Larsen, M. H., Mikkelsen, J. D., Hay-Schmidt, A., & Sandi, C. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.01.005 · Cited by 165 · cited 2×
“001 respectively) of mice exposed to UCMS, compared to the control non-stressed animals, which is consistent with the previous data [54,55].”
ResultToward Circuit Mechanisms of Pathophysiology in Depression
Spellman, T., & Liston, C. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20030280 · Cited by 165
Neurotrophic factors: From structure-function studies to designing effective therapeutics
Ibáñez, C. F. (1995) · Trends in biotechnology · doi:10.1016/s0167-7799(00)88949-0 · Cited by 150 · cited 1×
“In particular, residues 91–97 of the 4th loop of BDNF (Thr91-Met92-Asp93-Ser94-Lys95-Lys96-Arg97) have been recognized as one of the sites for neurotrophin/TrkB complex formation (reviewed in [37,38]).”
BackgroundQiao, H., An, S.-C., Xu, C. S., & Ma, X. (2017) · Brain Research · doi:10.1016/j.brainres.2017.02.020 · Cited by 141 · cited 1×
“It is well known that long-term exposure to stress, as well as other conditions that contribute to the depressive-like behavior in animals, is accompanied by a BDNF expression decrease in the prefrontal cortex and in the hippocampus, while an increase in the level of neurotrophin has been observed in the nucleus accum…”
BackgroundMolecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133 · cited 1×
“A rapidly developing and sustained antidepressant effect of ketamine which depends on the NMDA receptors inhibition, leads to the activation of mTORC1 complex followed by an increase in the translation and release of BDNF, an enhancement of BDNF/TrkB signaling, and a subsequent activation of the related cellular plast…”
BackgroundRantamäki, T., Vesa, L., Antila, H., Di Lieto, A., Tammela, P., Schmitt, A., Lesch, K.-P., Rios, M., & Castrén, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020567 · Cited by 124 · cited 1×
“[19,20] have demonstrated that, unlike BDNF, which requires prolonged administration of antidepressants to get a level increase, activation of the TrkB receptor in the cortex and hippocampus can occur upon even acute”
BackgroundYagasaki, Y., Numakawa, T., Kumamaru, E., Hayashi, T., Su, T.-P., & Kunugi, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508157200 · Cited by 122
Delgado y Palacios, R., Campo, A., Henningsen, K., Verhoye, M., Poot, D., Dijkstra, J., Van Audekerke, J., Benveniste, H., Sijbers, J., Wiborg, O., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.05.014 · Cited by 113
Alme, M. N., Wibrand, K., Dagestad, G., & Bramham, C. R. (2007) · Neural Plasticity · doi:10.1155/2007/26496 · Cited by 103
Tornese, P., Sala, N., Bonini, D., Bonifacino, T., La Via, L., Milanese, M., Treccani, G., Seguini, M., Ieraci, A., Mingardi, J., et al. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100160 · Cited by 101
From synapse to nucleus: Novel targets for treating depression
Covington, H. E., Vialou, V., & Nestler, E. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.004 · Cited by 98 · cited 1×
“Experimental studies have reported that the delayed onset of antidepressants action is associated with a slowly developed increase and rearrangements of synaptic strength in the depressionrelated circuits, requiring changes in the gene expression and protein translation that are dependent, to some extent, on the engag…”
BackgroundKvarta, M. D., Bradbrook, K. E., Dantrassy, H. M., Bailey, A. M., & Thompson, S. M. (2015) · Journal of Neurophysiology · doi:10.1152/jn.00359.2015 · Cited by 86 · cited 1×
“It has been experimentally established that the development of a depressive phenotype in UCMS is based on the elevated functionality of the hypothalamus-pituitary-adrenal (HPA) axis and its effects on the feedback systems of the limbic structures [59,60].”
BackgroundBarriga, G. G.-D., Giralt, A., Anglada‐Huguet, M., Gaja‐Capdevila, N., Orlandi, J. G., Soriano, J., Canals, J. M., & Alberch, J. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx198 · Cited by 84 · cited 1×
“Another interesting fact is that 7,8-dihydroxyflavone treatment triggered phosphorylation of TrkBY816 but not TrkBY515 with subsequent activation of the PLC-γ1 pathway in primary striatal neurons and selectively reverted the decrease of pTyr816 but not pTyr515 in striatum of the chronically treated R6/1 transgenic mic…”
BackgroundEffects of chronic mild stress on behavioral and neurobiological parameters — Role of glucocorticoid
Chen, J., Wang, Z., Zuo, W., Zhang, S., Chu, S., & Chen, N. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.11.006 · Cited by 83 · cited 1×
“It has been experimentally established that the development of a depressive phenotype in UCMS is based on the elevated functionality of the hypothalamus-pituitary-adrenal (HPA) axis and its effects on the feedback systems of the limbic structures [59,60].”
BackgroundMolecular Basis of Neurotrophin−Receptor Interactions
Pattarawarapan, M., & Burgess, K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030221q · Cited by 83 · cited 1×
“In particular, residues 91–97 of the 4th loop of BDNF (Thr91-Met92-Asp93-Ser94-Lys95-Lys96-Arg97) have been recognized as one of the sites for neurotrophin/TrkB complex formation (reviewed in [37,38]).”
BackgroundGPR56/ADGRG1 is associated with response to antidepressant treatment
Belzeaux-R, R., Gorgievski, V., Fiori, L. M., López, J. P., Grenier, J., Lin, R., Nagy, C., Ibrahim, E. C., Gascon, E., Courtet, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15423-5 · Cited by 74 · cited 2×
“and depression-like scores in the tests of learned helplessness such as the Porsolt test [48– 50], while antidepressants eliminate those manifestations [51,52].”
BackgroundChanged Synaptic Plasticity in Neural Circuits of Depressive-Like and Escitalopram-Treated Rats
Li, X.-L., Yuan, Y.-G., Xu, H., Wu, D., Gong, W.-G., Geng, L.-Y., Wu, F.-F., Tang, H., Xu, L., & Zhang, Z.-J. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv046 · Cited by 72 · cited 1×
“UCMS has been found to cause an increased coherence of activity in the amygdala [65], along with an increase in the dendrites’ length, the density of dendritic spines [66–68], and synaptic proteins [66].”
BackgroundCorrelation of ERα/ERβ expression with dendritic and behavioural changes in CUMS mice
Sharma, H. R., & Thakur, M. K. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.03.041 · Cited by 62
Delgado y Palacios, R., Verhoye, M., Henningsen, K., Wiborg, O., & Van der Linden, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095077 · Cited by 59
Drug Targets in Neurotrophin Signaling in the Central and Peripheral Nervous System
Kashyap, M. P., Roberts, C. M., Waseem, M., & Tyagi, P. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0885-3 · Cited by 58
Gudasheva, T. A., Povarnina, P., Logvinov, I. O., Antipova, T. A., & Seredenin, S. B. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s118768 · Cited by 55 · cited 1×
“Whilst GSB-106 has been shown to mediate its neurotrophic [40,84], neuroprotective [85,86] and antidepressantlike [87] effects through the TrkB-dependent pathways, the mechanisms, underlying this interplay remained rather elusive, since we have not yet explored the direct association of GSB-106 with TrkB.”
BackgroundDesign and synthesis of dipeptide mimetics of the brain-derived neurotrophic factor
Гудашева, Т. А., Тарасюк, А. В., Помогайбо, С. В., Логвинов, И. О., Povarnina, P. Y., Антипова, Т. А., & Середенин, С. Б. (2012) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162012030053 · Cited by 54 · cited 7×
“and antidepressant activity ANA-12 [35], and the low molecular weight BDNF mimetic GSB-106 [36].”
BackgroundMethodInfluentialNeurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm
Josephy-Hernandez, S., Jmaeff, S., Pirvulescu, I., Aboulkassim, T., & Saragovi, H. U. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.004 · Cited by 54
7,8-Dihydroxyflavone reverses the depressive symptoms in mouse chronic mild stress
Zhang, M.-W., Zhang, S.-F., Li, Z.-H., & Han, F. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.035 · Cited by 46 · cited 3×
“The best characterized and well-studied examples are the 7,8-dihydroxyflavone [32,33] and its synthetic derivative [34], the low-molecular weight TrkB antagonist with anxiolytic”
BackgroundTrkB neurotrophin receptor at the core of antidepressant effects, but how?
Rantamäki, T. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-02985-6 · Cited by 45 · cited 3×
“Abundant evidence indicates that action mechanisms of pharmacologically diverse antidepressants implicate a phosphorylation and an activation/transactivation of the TrkB receptors in the brain regions is associated with the depression-like behavior [24].”
BackgroundResultTargeting TrkB neurotrophin receptor to treat depression
Rantamäki, T., & Castrén, E. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.705 · Cited by 40 · cited 1×
“Overall, a number of previous observations as well as some more recent evidence emphasize the significance of TrkB as a valuable target for antidepressants [23,24] and reaffirm the critical role of BDNF/TrkB signaling in the pathophysiology of depression and in antidepressants action [7,25,26].”
ResultAn updated classification of antidepressants: A proposal to simplify treatment
Alvano, S. A., & Zieher, L. M. (2019) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2019.04.002 · Cited by 40 · cited 1×
“To date, clinically active antidepressants target primarily the monoamine systems in the brain, inhibiting the reuptake of monoamines (selective serotonin or/and noradrenaline and dopamine reuptake inhibitors, tricyclic antidepressants), decreasing their degradation rate (inhibitors of monoamine oxidase), or acting on…”
BackgroundГудашева, Т. А., Логвинов, И. О., Антипова, Т. А., & Середенин, С. Б. (2013) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672913040121 · Cited by 33 · cited 2×
“Whilst GSB-106 has been shown to mediate its neurotrophic [40,84], neuroprotective [85,86] and antidepressantlike [87] effects through the TrkB-dependent pathways, the mechanisms, underlying this interplay remained rather elusive, since we have not yet explored the direct association of GSB-106 with TrkB.”
BackgroundAntidepressant Effect of Dimeric Dipeptide GSB-106, an Original Low-Molecular-Weight Mimetic of BDNF
Середенин, С. Б., Воронина, Т. А., Гудашева, Т. А., Гарибова, Т. Л., Молодавкин, Г. М., Литвинова, С. А., Елизарова, О. А., & Посева, В. И. (2013) · Acta Naturae · doi:10.32607/20758251-2013-5-4-105-109 · Cited by 32
Гудашева, Т. А., Povarnina, P. Y., Тарасюк, А. В., & Середенин, С. Б. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190329122852 · Cited by 30 · cited 1×
“Whilst GSB-106 has been shown to mediate its neurotrophic [40,84], neuroprotective [85,86] and antidepressantlike [87] effects through the TrkB-dependent pathways, the mechanisms, underlying this interplay remained rather elusive, since we have not yet explored the direct association of GSB-106 with TrkB.”
BackgroundГудашева, Т. А., Таллерова, А. В., Межлумян, А. Г., Антипова, Т. А., Логвинов, И. О., Firsova, Y. N., Povarnina, P. Y., & Середенин, С. Б. (2021) · Biomolecules · doi:10.3390/biom11020252 · Cited by 29 · cited 1×
“GSB-106 (21 days, per os) has been shown to restore the reduced levels of synaptophysin and CREB in the hippocampus of C57BL/6 mice subjected to the 28-days chronic social defeat stress [45].”
BackgroundDipeptide Mimetics of Different NGF and BDNF Loops Activate PLC-γ1
Гудашева, Т. А., Логвинов, И. О., Николаев, С. В., Антипова, Т. А., Povarnina, P. Y., & Середенин, С. Б. (2020) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672920050075 · Cited by 26 · cited 1×
“The compound has been shown to exert a trophic effect, up-regulate the TrkB phosphorylation and downstream PI3K/Akt, MAPK/Erk and PLCγ signaling pathways in vitro [40,41].”
BackgroundPovarnina, P. Y., Гарибова, Т. Л., Гудашева, Т. А., & Середенин, С. Б. (2018) · Acta Naturae · doi:10.32607/20758251-2018-10-3-81-83 · Cited by 22
Зайнуллина, Л. Ф., Vakhitova, Y. V., Lusta, A. Y., Гудашева, Т. А., & Середенин, С. Б. (2021) · Scientific Reports · doi:10.1038/s41598-021-87435-0 · Cited by 21 · cited 2×
“Furthermore, GSB-106 has been found to act as a partial TrkB receptor agonist, promoting protection of serum-deprived neuronal-like cells by counteracting cell apoptosis through the activation of TrkB-dependent pro-survival mechanisms, including inactivation of pro-apoptotic BAD protein and suppression of caspases 9 a…”
BackgroundSelf-citationKudryashov, N. V., Kalinina, T. C., Shimshirt, A. A., Волкова, А. В., Наркевич, В. Б., Naplekova, P. L., Касабов, К. А., Kudrin, V. C., Воронина, Т. А., & Фисенко, В. П. (2020) · Acta Naturae · doi:10.32607/actanaturae.10942 · Cited by 13 · cited 2×
“and depression-like scores in the tests of learned helplessness such as the Porsolt test [48– 50], while antidepressants eliminate those manifestations [51,52].”
BackgroundSelf-citationUtility of the chronic unpredictable mild stress model in research on new antidepressants
Pękała, K., Budzyńska, B., & Biała, G. (2014) · Current Issues in Pharmacy and Medical Sciences · doi:10.2478/cipms-2014-0022 · Cited by 11 · cited 1×
“Complicated etiology of depression involves large number of factors including stressful life events, genetic risk, and type of personality response to the adverse life experiences [2].”
BackgroundLi, X., Wang, H., Chen, Q., Li, Z., Liu, C., Yin, S., & You, Z. (2019) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12466 · Cited by 11
Таллерова, А. В., Межлумян, А. Г., Яркова, М. А., Гудашева, Т. А., & Середенин, С. Б. (2021) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-021-02397-x · Cited by 8
Dimeric Dipeptide Mimetics of NGF and BDNF Are Promising Agents for Post-Stroke Therapy
Povarnina, P. Y., Гудашева, Т. А., & Середенин, С. Б. (2018) · Journal of Biomedical Science and Engineering · doi:10.4236/jbise.2018.115009 · Cited by 7 · cited 1×
“Whilst GSB-106 has been shown to mediate its neurotrophic [40,84], neuroprotective [85,86] and antidepressantlike [87] effects through the TrkB-dependent pathways, the mechanisms, underlying this interplay remained rather elusive, since we have not yet explored the direct association of GSB-106 with TrkB.”
BackgroundLow-Molecular-Weight Compound GSB-106 Mimics the Cellular Effects of BDNF after Serum Deprivation
Зайнуллина, Л. Ф., Гудашева, Т. А., Vakhitova, Y. V., & Середенин, С. Б. (2019) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672919060139 · Cited by 6 · cited 1×
“Whilst GSB-106 has been shown to mediate its neurotrophic [40,84], neuroprotective [85,86] and antidepressantlike [87] effects through the TrkB-dependent pathways, the mechanisms, underlying this interplay remained rather elusive, since we have not yet explored the direct association of GSB-106 with TrkB.”
BackgroundSelf-citation
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“Two BDNF mimickers currently under investigation are dipeptide N-monosuccinyl-L-seryl-L-lysine and 7,8-Dihydroxyflavone (187).”
BackgroundStress-Induced Depression and Alzheimer’s Disease: Focus on Astrocytes
Dolotov, O. V., Inozemtseva, L. S., Myasoedov, N. F., & Grivennikov, I. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094999 · Cited by 110
“Another promising approach, in our opinion, is associated with the use of short peptide mimetics of BDNF, which are able to activate TrkB receptors demonstrating a pronounced antidepressant effects [210].”
BackgroundNeurotrophin-targeted therapeutics: A gateway to cognition and more?
Nordvall, G., Forsell, P., & Sandin, J. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.07.003 · Cited by 48
Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer's disease
Zota, I., Chanoumidou, K., Gravanis, A., & Charalampopoulos, I. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1422130 · Cited by 25
Charou, D., Rogdakis, T., Latorrata, A., Valcárcel, M., Papadogiannis, V., Athanasiou, C., Tsengenes, A., Papadopoulou, M. A., Lypitkas, D., Lavigne, M. D., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03818-w · Cited by 18
Metadata
- Authors
- Vakhitova, Y. V., Kalinina, T. S., Zainullina, L. F., Lusta, A. Y., Volkova, A. V., Kudryashov, N. V., Gudasheva, T. A., Shimshirt, A. A., Kadnikov, I. A., Voronin, M. V., & Seredenin, S. B.
- Affiliations
- Institute of Pharmacology Russian Academy of Medical Sciences (RU)
- Department of Psychopharmacology, FSBI “Zakusov Institute of Pharmacology”, Baltiyskaya Street 8, 125315 Moscow, Russia
- Department of Pharmacogenetics, FSBI “Zakusov Institute of Pharmacology”, Baltiyskaya Street 8, 125315 Moscow, Russia
- Department of Medicinal Chemistry, FSBI “Zakusov Institute of Pharmacology”, Baltiyskaya Street 8, 125315 Moscow, Russia
- Corresponding author
- Vakhitova, Yulia V.
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-12-13
- Volume
- 22
- Issue
- 24
- Pages
- 13381
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8704497
- OpenAlex
- W4200538075
- Cited by
- 21
- References
- 88
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 7 · 2023: 5 · 2022: 5
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Higher Education of the Russian Federation (Project 0521-2019-0002)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- antidepressant-like effects, BDNF/TrkB signaling, TrkB phosphorylation, BDNF mimetic, chronic unpredictable mild stress, depression, prefrontal cortex, hippocampus, rapid-acting antidepressants
- MeSH terms
- Animals, Antidepressive Agents, Brain, Dipeptides, Hippocampus, Male, Membrane Glycoproteins, Mice, Inbred BALB C, Protein-Tyrosine Kinases, Stress, Psychological, Signal Transduction, Prefrontal Cortex, Brain-Derived Neurotrophic Factor, Receptor, trkB, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.